Navigating the FDA's Final Interim Policy on Compounding with Bulk Drug Substances: A Guide for 503A Pharmacies and 503B Outsourcing Facilities Buchanan Ingersoll & Rooney PC When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions FDA Moves to Reevaluate Several Peptides American Med Spa Association FDA Removes Key Peptides from Category 2: What This Means for You The FDA may be about to change everything for peptide research. Secretary RFK Jr. announced plans to move 14 peptides from Category 2 to Category 1. That means FDA recognized. Potentially prescribable through Clinical and Legal Considerations in Pharmaceutical Compounding JCAD The Journal of Clinical and Aesthetic Dermatology